Literature DB >> 10751229

Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure.

D Portilla1, G Dai, J M Peters, F J Gonzalez, M D Crew, A D Proia.   

Abstract

Regulation of fatty acid beta-oxidation (FAO) represents an important mechanism for a sustained balance of energy production/utilization in kidney tissue. To examine the role of stimulated FAO during ischemia, Etomoxir (Eto), clofibrate, and WY-14,643 compounds were given 5 days prior to the induction of ischemia/reperfusion (I/R) injury. Compared with rats administered vehicle, Eto-, clofibrate-, and WY-treated rats had lower blood urea nitrogen and serum creatinines following I/R injury. Histological analysis confirmed a significant amelioration of acute tubular necrosis. I/R injury led to a threefold reduction of mRNA and protein levels of acyl CoA oxidase (AOX) and cytochrome P4A1, as well as twofold inhibition of their enzymatic activities. Eto treatment prevented the reduction of mRNA and protein levels and the inhibition of the enzymatic activities of these two peroxisome proliferator-activated receptor-alpha (PPARalpha) target genes during I/R injury. PPARalpha null mice subjected to I/R injury demonstrated significantly enhanced cortical necrosis and worse kidney function compared with wild-type controls. These results suggest that upregulation of PPARalpha-modulated FAO genes has an important role in the observed cytoprotection during I/R injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751229     DOI: 10.1152/ajprenal.2000.278.4.F667

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  51 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

Review 3.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 4.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

5.  Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury.

Authors:  Kevin R Regner; Anna Zuk; Scott K Van Why; Brian D Shames; Robert P Ryan; John R Falck; Vijay L Manthati; Meghan E McMullen; Steven R Ledbetter; Richard J Roman
Journal:  Kidney Int       Date:  2008-12-03       Impact factor: 10.612

6.  Deficiency in the Formation of 20-Hydroxyeicosatetraenoic Acid Enhances Renal Ischemia-Reperfusion Injury.

Authors:  Yoshikazu Muroya; Fan Fan; Kevin R Regner; John R Falck; Michael R Garrett; Luis A Juncos; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

7.  Serum metabolomic profiles from patients with acute kidney injury: a pilot study.

Authors:  Jinchun Sun; Melissa Shannon; Yosuke Ando; Laura K Schnackenberg; Nasim A Khan; Didier Portilla; Richard D Beger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-06       Impact factor: 3.205

8.  Role of PPARα and Its Agonist in Renal Diseases.

Authors:  Ching-Feng Cheng; Hsi-Hsien Chen; Heng Lin
Journal:  PPAR Res       Date:  2010-11-08       Impact factor: 4.964

Review 9.  Peroxisomes and Kidney Injury.

Authors:  Radovan Vasko
Journal:  Antioxid Redox Signal       Date:  2016-04-22       Impact factor: 8.401

10.  Analysis of the heat shock response in mouse liver reveals transcriptional dependence on the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha).

Authors:  Beena Vallanat; Steven P Anderson; Holly M Brown-Borg; Hongzu Ren; Sander Kersten; Sudhakar Jonnalagadda; Rajagopalan Srinivasan; J Christopher Corton
Journal:  BMC Genomics       Date:  2010-01-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.